Buscar
Quoin Pharmaceuticals Ltd
QNRXAñadir a la lista de seguimiento
6.900USD
-0.070-1.00%
Cierre 09-10 16:00（ET）
486.44MCap. mercado
PérdidaP/E TTM
Fuera de horario (ET)0.000USD0.000
Fuera de horario (ET)Más Datos de Quoin Pharmaceuticals Ltd Compañía
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
Perfil de Quoin Pharmaceuticals Ltd
Símbolo de cotizaciónQNRX
Nombre de la empresaQuoin Pharmaceuticals Ltd
Fecha de salida a bolsaNov 01, 1989
Director ejecutivoMyers (Michael)
Número de empleados3
Tipo de seguridadDepository Receipt
Fin del año fiscalNov 01
Dirección23 Hata'as Street
CiudadKFAR SABA
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIsrael
Código postal44425
Teléfono97299741444
Sitio Webhttps://quoinpharma.com/
Símbolo de cotizaciónQNRX
Fecha de salida a bolsaNov 01, 1989
Director ejecutivoMyers (Michael)
Ejecutivos de Quoin Pharmaceuticals Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Michael Myers, Ph.D.
Dr. Michael Myers, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
37.71K
+54.33%
Ms. Sally Lawlor
Ms. Sally Lawlor
Chief Financial Officer
Chief Financial Officer
10.68K
+95.88%
Dr. Amotz Nehushtan
Dr. Amotz Nehushtan
Vice President - Research & Development & Product Development
Vice President - Research & Development & Product Development
--
--
Mr. Guy Sapir
Mr. Guy Sapir
Internal Auditor
Internal Auditor
--
--
Dr. Amos Ofer
Dr. Amos Ofer
Chief Operating Officer, Vice President
Chief Operating Officer, Vice President
--
--
Mr. David L. Braun
Mr. David L. Braun
Independent Director
Independent Director
--
--
Mr. Jonathan Burgin, CPA
Mr. Jonathan Burgin, CPA
Independent External Director
Independent External Director
--
--
Ms. Ronit Biran
Ms. Ronit Biran
Independent Director
Independent Director
--
--
Mr. Yali Sheffi
Mr. Yali Sheffi
Independent External Director
Independent External Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Michael Myers, Ph.D.
Dr. Michael Myers, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
37.71K
+54.33%
Ms. Sally Lawlor
Ms. Sally Lawlor
Chief Financial Officer
Chief Financial Officer
10.68K
+95.88%
Dr. Amotz Nehushtan
Dr. Amotz Nehushtan
Vice President - Research & Development & Product Development
Vice President - Research & Development & Product Development
--
--
Mr. Guy Sapir
Mr. Guy Sapir
Internal Auditor
Internal Auditor
--
--
Dr. Amos Ofer
Dr. Amos Ofer
Chief Operating Officer, Vice President
Chief Operating Officer, Vice President
--
--
Mr. David L. Braun
Mr. David L. Braun
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Quoin Pharmaceuticals Ltd?
Los cinco principales accionistas de Quoin Pharmaceuticals Ltd son: Dr. Michael Myers, Ph.D.
¿Cuántas instituciones poseen acciones de Quoin Pharmaceuticals Ltd (QNRX)?
A fecha de 2026Q1, 40 instituciones poseen acciones de Quoin Pharmaceuticals Ltd, con un valor de mercado combinado de aproximadamente 874.98K, lo que representa el 43.66% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 369388.00.